Lupus Foundation of America supported study finds combination therapy that includes hydroxychloroquine may be beneficial to pregnant patients with lupus and/or antiphospholipid syndrome.
A recent review of lupus quality of life studies found five common themes that describe the experiences of adults living with lupus. Healthcare providers can now use these themes to develop and expand patient-focused care and support services that will improve health and treatment outcomes.
New Tool Helps to Ensure Better Representation of Minorities in Future Lupus Quality of Life Studies
Researchers now have a cost effective tool to help them better understand the burden of disease among populations at high risk for developing lupus. Learn more.
Children with lupus may have a higher risk for developing cancer – especially blood cancers such as non-Hodgkin’s lymphoma and leukemia – compared to children without lupus.
A new study that analyzed lupus treatment data from past global clinical trials suggests that when testing new drugs in combination with other background therapies, clinical trials should be designed to account for the effects that initial disease activity and background drug treatment have been shown to have on planned endpoints, like response and flare rates.
The outlook for positive pregnancy outcomes for women with lupus remains bright, but data obtained from a large insurance claims database highlights the need for specific education and counseling to pregnant women with lupus as well as close collaboration between the rheumatologist and the obstetrician throughout the pregnancy.
Although the overall risk is small, children born to mothers with lupus may have a higher risk of autism spectrum disorders than children born to mothers without the disease, according to the results of a study presented this week at the American College of Rheumatology Annual Scientific Meeting in San Diego.
According to research presented this week at the American College of Rheumatology Annual Meeting, researchers have identified three potentially modifiable risk factors and one protective medication that may improve the health of people living with lupus.